We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New Company To Promote and Commercialize bioMerieux Range in Japan

By HospiMedica staff writers
Posted on 22 Jan 2008
Sysmex Corp. More...
(Kobe, Japan; www.sysmex.com) and bioMerieux (Marcy l'Etoile, France; www.biomerieux.com) have signed an agreement to form a new company called Sysmex bioMerieux, Ltd. The company will promote and commercialize the entire bioMerieux product range in Japan.

bioMerieux has been operating in the Japanese clinical diagnostics and industrial testing market through bioMerieux Japan, Ltd., a fully owned subsidiary. The joint venture (JV) will manage the regulatory filing and marketing activities of bioMerieux product ranges in Japan. The sales and customer service activities will be contracted out from the JV to Sysmex.

Sysmex and bioMerieux have been developing their global partnership since July 2007, when bioMerieux became a global partner to distribute Sysmex's highly standardized and automated UF-1000i urine sediment analyzer to their extensive clinical microbiology customer base.

bioMérieux provides diagnostic products (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

Sysmex performs clinical laboratory testing of blood, urine, and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems. The company, which specialized in hematology, has expanded to offer a comprehensive range of diagnostics products and solutions in the diagnostics field including coagulation, biochemistry, immunochemistry, urinalysis, and other disciplines.

The market volume of microbiology testing in Japan is estimated at approximately US$280 million per year and is regarded as a strategically important market, the second largest in size worldwide.


Related Links:
Sysmex Corporation
bioMerieux

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
OR Table Accessory
Angular Accessory Rail
Xenon Light Source
CLV-S400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.